Nagendra Boopathy Senguttuvan1,2,3, Ramesh Sankaran4, Yashasvi Rajeev5, Devi Thaiyal6, Angel Mathew6, K Dharsini6, Divya Marcelene6, Maria Jusler Kalsingh7, Sujit Kumar Sahu6, Aravind Sampath6, K J Prem Kumar6, Harikrishnan Parthasarathy6, Amal Louis6, Anand Gnanaraj6, K N Reddy6, K A Abraham6. 1. Department of Cardiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India. nagendraboopathy@sriramachandra.edu.in. 2. Adjunct Faculty-Indian Institute of Technology Madras, Chennai, Tamil Nadu, India. nagendraboopathy@sriramachandra.edu.in. 3. Department of Cardiology, Apollo Specialty Hospitals, Chennai, Tamil Nadu, India. nagendraboopathy@sriramachandra.edu.in. 4. Department of Cardiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India. 5. Department of Cardiology, Jaswant Rai Specialty Hospitals, Chennai, Tamil Nadu, India. 6. Department of Cardiology, Apollo Specialty Hospitals, Chennai, Tamil Nadu, India. 7. National Health Mission, Chennai, Tamil Nadu, India.
Abstract
BACKGROUND: Dual antiplatelet therapy is the current standard of care after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). We intended to study the pattern of use of ticagrelor in patients with acute coronary syndrome undergoing PCI and the effect of switching over to other P2Y12 receptor inhibition on clinical outcomes. RESULTS: All patients aged > 18 years who had been admitted with acute coronary syndrome and had been provided ticagrelor as the second antiplatelet agent were included as study participants. The primary outcome of the study was the composite outcome of death, recurrent myocardial infarctions, re-intervention, and major bleeding. We studied 321 patients (54 female patients, 16.82%). The mean age of the patients was 56.65 ± 11.01 years. Ticagrelor was stopped in 76.7% on follow-up. It was stopped in 6.3%, 13.5%, 13.1%, 21.9%, and 45.1% of patients during the first month but after discharge, between first and third months, between 3 and 6 months, between 6 and 12 months, and after 12 months, respectively. In the majority of patients, ticagrelor was replaced by clopidogrel (97.9%). It was stopped according to the physician's discretion in 79.3% of patients, whereas it was the cost of the drug that made the patient to get swapped to another agent in 18.6%. No difference in the primary composite outcome was observed between the groups where ticagrelor was continued post 12 months and ticagrelor was continued and ticagrelor was switched-over to another agent. Similarly, no difference in death, recurrent myocardial infarctions, re-interventions, or major bleeding manifestations was observed between the two groups. CONCLUSION: In patients with acute coronary syndrome who undergo PCI, we observed that early discontinuation of ticagrelor and switching over to other P2Y12 inhibitors after discharge did not affect clinical outcomes.
BACKGROUND: Dual antiplatelet therapy is the current standard of care after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). We intended to study the pattern of use of ticagrelor in patients with acute coronary syndrome undergoing PCI and the effect of switching over to other P2Y12 receptor inhibition on clinical outcomes. RESULTS: All patients aged > 18 years who had been admitted with acute coronary syndrome and had been provided ticagrelor as the second antiplatelet agent were included as study participants. The primary outcome of the study was the composite outcome of death, recurrent myocardial infarctions, re-intervention, and major bleeding. We studied 321 patients (54 female patients, 16.82%). The mean age of the patients was 56.65 ± 11.01 years. Ticagrelor was stopped in 76.7% on follow-up. It was stopped in 6.3%, 13.5%, 13.1%, 21.9%, and 45.1% of patients during the first month but after discharge, between first and third months, between 3 and 6 months, between 6 and 12 months, and after 12 months, respectively. In the majority of patients, ticagrelor was replaced by clopidogrel (97.9%). It was stopped according to the physician's discretion in 79.3% of patients, whereas it was the cost of the drug that made the patient to get swapped to another agent in 18.6%. No difference in the primary composite outcome was observed between the groups where ticagrelor was continued post 12 months and ticagrelor was continued and ticagrelor was switched-over to another agent. Similarly, no difference in death, recurrent myocardial infarctions, re-interventions, or major bleeding manifestations was observed between the two groups. CONCLUSION: In patients with acute coronary syndrome who undergo PCI, we observed that early discontinuation of ticagrelor and switching over to other P2Y12 inhibitors after discharge did not affect clinical outcomes.
Authors: Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith Journal: Circulation Date: 2016-03-29 Impact factor: 29.690
Authors: Anders Sahlén; Christoph Varenhorst; Bo Lagerqvist; Henrik Renlund; Elmir Omerovic; David Erlinge; Lars Wallentin; Stefan K James; Tomas Jernberg Journal: Eur Heart J Date: 2016-07-19 Impact factor: 29.983
Authors: Dominick J Angiolillo; Fabiana Rollini; Robert F Storey; Deepak L Bhatt; Stefan James; David J Schneider; Dirk Sibbing; Derek Y F So; Dietmar Trenk; Dimitrios Alexopoulos; Paul A Gurbel; Willibald Hochholzer; Leonardo De Luca; Laurent Bonello; Daniel Aradi; Thomas Cuisset; Udaya S Tantry; Tracy Y Wang; Marco Valgimigli; Ron Waksman; Roxana Mehran; Gilles Montalescot; Francesco Franchi; Matthew J Price Journal: Circulation Date: 2017-10-30 Impact factor: 29.690
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Pierre Deharo; Jacques Quilici; Laurence Camoin-Jau; Thomas W Johnson; Clémence Bassez; Guillaume Bonnet; Marianne Fernandez; Manal Ibrahim; Pierre Suchon; Valentine Verdier; Laurent Fourcade; Pierre Emmanuel Morange; Jean Louis Bonnet; Marie Christine Alessi; Thomas Cuisset Journal: JACC Cardiovasc Interv Date: 2017-12-26 Impact factor: 11.195
Authors: Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: M N Krishnan; G Zachariah; K Venugopal; P P Mohanan; S Harikrishnan; G Sanjay; L Jeyaseelan; K R Thankappan Journal: BMC Cardiovasc Disord Date: 2016-01-14 Impact factor: 2.298
Authors: Thomas Cuisset; Pierre Deharo; Jacques Quilici; Thomas W Johnson; Stéphanie Deffarges; Clémence Bassez; Guillaume Bonnet; Laurent Fourcade; Jean Philippe Mouret; Marc Lambert; Valentine Verdier; Pierre Emmanuel Morange; Marie Christine Alessi; Jean Louis Bonnet Journal: Eur Heart J Date: 2017-11-01 Impact factor: 29.983